World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016

Jerome Galon, Alessandro Lugli, Carlo Bifulco, Franck Pages, Giuseppe Masucci, Francesco M Marincola, Paolo A Ascierto

Research output: Contribution to journalArticlepeer-review


The predictive accuracy of the traditional staging system is based on disease progression as a tumour cell-autonomous process, but it fails to incorporate the effects of the host immune response. A precise analysis of the immune component of the tumour microenvironment by computer-based analysis may be essential to managing patients better, opening the road to an expertise in this new emerging field. The Immunoscore as a new possible approach in the classification of cancer, designated TNM-Immune, studied in colon cancer patients with predictive and prognostic value. This new scoring system is derived from the immune contexture, and is based on the numeration of lymphocyte populations, both in the core of the tumour and in the invasive margin of tumours. The Immunoscore demonstrated to be quantitative, reproducible and robust. The usefulness of Immunoscore in advanced melanoma cancer patients has been as well demonstrated; the correlation of marker expression profile with clinical outcome is ongoing. More recently, the Immunoscore could be a useful prognostic marker in patients with rectal cancer treated by primary surgery. A multivariable Cumulative "Suppression Index" scoring system has been also studied in Oral Squamous Cell Carcinoma patients: it evaluates both the tumor and stromal microcompartments at the invasive margin and summarizes them into the score, providing an accurate stratification, independent of stage, tumour classification. The introduction of Immunoscore requires a redefinition of the Laboratory system according to the LEAN Management process, which has been already implemented in referral research labs. The definition and test of hundreds of biomarkers, in the tumour contexture represents a definitive scientific progression. However, there is still a need of substantial body of work to reach the end of the tunnel to assure a personalize treatment.

Original languageEnglish
Pages (from-to)212
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Oct 20 2017


  • Journal Article


Dive into the research topics of 'World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016'. Together they form a unique fingerprint.

Cite this